Title: PREVENTION OF TYPE 2 DIABETES
1PREVENTION OFTYPE 2 DIABETES
- Francine Ratner Kaufman, M.D.
- Professor of Pediatrics
- The Keck School of Medicine of USC
- Head, Center of Diabetes, Endocrinology and
Metabolism - Childrens Hospital Los Angeles
- President, American Diabetes Association
2Burden of Diabetes in USA
- 17 Million Americans Have Diabetes
- 16 Million Americans Have Prediabetes
- 210,000 Diabetes-Related Deaths/year
- Leading Cause of Blindness, Kidney Failure,
Amputation - 65 Cardiovascular Disease-Related Death
- Cost 132 Billion/2002
Mokdad, et al, JAMA 2001 286,1195
3Diabetes Prevalence Among Minority Populations in
the U.S.
Percentage of each population with diabetes
Non-Hispanic Whites
Latinos
African Americans
Native Americans Alaska Natives
7.8 (11.4 million)
10.2 (2 million)
13 (2.8 million)
15.1 (105,000)
?
Asian Americans and Pacific Islanders are 2-5
times more likely to have diabetes than
Non-Hispanic Whites.
Centers for Disease Control and Prevention (CDC)
1999 www.cdc.gov/diabetes
4Natural History of Type 2 Diabetes
Onset ofdiabetes
Geneticsusceptibility Environmentalfactors Nutr
ition Obesity Physical inactivity
Complications
Disability
IGT
Ongoing hyperglycemia
Insulin resistance
Death
Hyperinsulinemia HDL-C TriglyceridesAtheroscl
erosisHypertension
BlindnessRenal failureCHDAmputation
RetinopathyNephropathyNeuropathy
AtherosclerosisHyperglycemiaHypertension
5The Diabetes Prevention Program A Randomized
Clinical Trial to Prevent Type 2 Diabetes in
Persons at High Risk The DPP Research Group
6Study Interventions
Eligible participants Randomized Standard
lifestyle recommendations
Intensive DRUG
Placebo Lifestyle Metformin (n 1079)
(n 1073) (n 1082)
7Weight Change
Placebo
Metformin
Lifestyle
The DPP Research Group, NEJM 346393-403, 2002
8Type 2 Diabetes Prevention
Percent developing diabetes
Risk reduction 31 by metformin 58 by lifestyle
All participants
All participants
Lifestyle (n1079, pPlac )
Metformin (n1073, p40
Placebo (n1082)
30
Placebo
Metformin
Cumulative incidence ()
20
Lifestyle
10
0
0
1
2
3
4
Years from randomization
The DPP Research Group, NEJM 346393-403, 2002
9Prevention of Type 2 with Lifestyle Intervention
Tuomilehto, et al , Turku ADA 2000
- Intervention 523 IGT, mean age 55, BMI 31
- Diet, exercise, frequent visits vs advice yearly
Incidence of diabetes reduced 58 (p.0003)
10DIABETES INCIDENCE IN PREVENTION STUDIES
11- Translation of the
- DPP Results
12ADA/NIDDK Screening Recommendations For
Prediabetes in AdultsDiabetes Care, 252002
- Case Finding
- Test
- 45 years, BMI 25 kg/m2
- 9 lbs,
dyslipidemia, hypertension, non-Caucasian - At 3 yr intervals, if negative
13ADA/NIDDK Recommendations In AdultsDiabetes
Care, 252002
- How to Test
- In context of health care visit
- FPG, 2-h OGTT
- Intervention
- Prediabetes counsel for weight loss and PA,
Follow-up counseling - Monitor for DM q 1-2 years, CVD risk factors
- Avoid drug therapy
14What Children Should be Tested ADA/AAP
RecommendationsDiabetes Care 232000
- Age 10 years or onset of puberty
- BMI 85th
- First or Second Degree Relative
- Race/Ethnic Group
- Signs of Insulin Resistance
- Acanthosis nigricans
- Hypertension
- PCOS
- Dyslipidemia
-
15Small Steps Big Rewards
Diabetes Prevention Program For People at High
Risk
- Weight Loss
- Diet
- Exercise
- Lower Risk for Diabetes
16Studies to Treat Or Prevent Pediatric Type 2
Diabetes(STOPP-T2D)
Funded by National Institute of Diabetes and
Digestive and Kidney Diseases National Institutes
of Health
TODAY
17Weight Loss Reduces Medical Costs
- Costs of diabetes 132 billion (2002)
- Direct Costs 5.7 National Health Expenditure
- 7 10 Weight Loss
- 58 Reduction in Diabetes
- Treatment Cost Reduction
- 123 for the insulin-treated patient/month
- 61 for the hyperlipidemic patient/month
(Wolf AM, Colditz GA. Obes Res. 1998) (Greenway
FL, et al. Obes Res. 1999)
18GLOBAL PROJECTIONS FOR THE DIABETES EPIDEMIC
2000-2010
26.5 32.9 24
14.2 17.5 23
84.5 132.3 57
9.4 14.1 50
1.0 1.3 33
15.6 22.5 44
World 2000 151 million 2010 221
million Increase 46